ヒアルロン酸の市場規模、シェア、動向分析レポート:用途別(皮膚充填剤、変形性関節症、眼科、膀胱尿管逆流)、地域別、セグメント別予測、2024年~2030年Hyaluronic Acid Market Size, Share & Trends Analysis Report By Application (Dermal Fillers, Osteoarthritis, Ophthalmic, Vesicoureteral Reflux), By Region, And Segment Forecasts, 2024 - 2030 ヒアルロン酸市場の成長と動向 Grand View Research, Inc.の新しいレポートによると、世界のヒアルロン酸市場規模は、2024年から2030年にかけて7.7%のCAGRを記録し、2030年までに167.5億米ドルに達すると予測... もっと見る
1~3営業日
サマリーヒアルロン酸市場の成長と動向Grand View Research, Inc.の新しいレポートによると、世界のヒアルロン酸市場規模は、2024年から2030年にかけて7.7%のCAGRを記録し、2030年までに167.5億米ドルに達すると予測されている。化学物質に対する人々の関心の高まり、迅速で明白な結果を得たいという願望、回復時間の短縮などの要因は、インパクトの強いレンダリング促進要因である。業界は、先進国や発展途上地域での美容施術の採用増加により急速に発展している。ステントや人工血管のような心血管系インプラントにおいて、適合性を向上させるためにヒアルロン酸表面の使用が増加しており、アンチエイジング製品に対する意識の高まりと相まって、成長を促進している。 ヒアルロン酸ベースの皮膚充填剤の有効性と明らかな結果が、この人口基盤を引き付けている。さらに、COVID-19の大流行は多くの産業の力学を変え、移動制限、社会的距離、慣行の見直しが「新常態」となっている。化粧品業界が徐々に営業を再開するなか、多くの医師が美容整形手術の問い合わせが大幅に増えたと報告している。さらに、鎖国によって各専門家がテレビ会議設備を利用するようになり、人々は自分の外見をより意識するようになった。場合によっては、美容整形を選ぶきっかけにもなっており、これは "ズーム・ブーム "あるいは "ズーム効果 "と呼ばれている。 世界中の美容外科医は、特に米国、オーストラリア、日本などの国々で、パンデミックの結果として患者数が大幅に増加していることを目の当たりにしている。2022年には北米が最大の売上シェアを占めた。高価格であっても短期治療レジメンが好まれること、変形性関節症などの対象疾患の流行が高いシェアの主な要因である。2022年、北米地域で最も有利な製品用途は、変形性関節症の管理用の皮膚充填剤とビスコス・サプリメントの形態であった。アジア太平洋地域は、予測期間中に最も速いCAGRを記録すると予測されている。 中国と日本では老年人口が増加しており、アンチエイジング製品およびサービスの大規模な顧客基盤となっている。製品の用途や効能に関する意識の高まりも需要を後押ししている。さらに、可処分所得水準の向上がこの地域の拡大をさらに後押ししている。欧州は過去2年間に目覚ましい変化を遂げた。需要の高まりは、新規参入企業による価格競争の激化を目の当たりにしている。WHOは最近、英国とドイツにおける肥満の蔓延を発表した。高齢化人口の増加と肥満の関係は、欧州地域セクターの潜在的な原動力である。 ヒアルロン酸市場レポートハイライト - 変形性関節症分野が世界業界を支配し、2023年には全体収益の最大シェアを占める - 肥満による変形性関節症や関節痛の増加により、治療としてのヒアルロン酸注射の需要が増加 - ヒアルロン酸はショックアブソーバーやクッションとして働き、関節を潤滑にするため、適切な機能を助ける。 - ヒアルロン酸/ヒアルロン酸を有効成分として使用した眼科手術用製品は数多くある。 - Vitrax、Healon、Amivisc Plus、Amvisc、Hylan G-F20、Opeganなどである。 - 加齢に伴う眼疾患、ドライアイ症候群、成人視力障害、糖尿病などの慢性疾患の有病率の増加が、このセグメントの成長を導く主な要因である。 目次Table of ContentsChapter 1. Methodology and Scope 1.1. Market Segmentation & Scope 1.2. Segment Definitions 1.2.1. Application 1.2.2. Regional scope 1.2.3. Estimates and forecasts timeline 1.3. Research Methodology 1.4. Information Procurement 1.4.1. Purchased database 1.4.2. GVR’s internal database 1.4.3. Secondary sources 1.4.4. Primary research 1.4.5. Details of primary research 1.4.5.1. Data for primary interviews in North America 1.4.5.2. Data for primary interviews in Europe 1.4.5.3. Data for primary interviews in Asia Pacific 1.4.5.4. Data for primary interviews in Latin America 1.4.5.5. Data for Primary interviews in MEA 1.5. Information or Data Analysis 1.5.1. Data analysis models 1.6. Market Formulation & Validation 1.7. Model Details 1.7.1. Commodity flow analysis (Model 1) 1.7.2. Approach 1: Commodity flow approach 1.7.3. Volume price analysis (Model 2) 1.7.4. Approach 2: Volume price analysis 1.8. List of Secondary Sources 1.9. List of Primary Sources 1.10. Objectives Chapter 2. Executive Summary 2.1. Market Outlook 2.2. Segment Outlook 2.2.1. Application 2.2.2. Regional outlook 2.3. Competitive Insights Chapter 3. Hyaluronic Acid Market Variables, Trends & Scope 3.1. Market Lineage Outlook 3.1.1. Parent market outlook 3.1.2. Related/ancillary market outlook 3.2. Market Dynamics 3.2.1. Market driver analysis 3.2.1.1. Increasing Geriatric Population 3.2.1.2. Growing Awareness for Antiaging Products 3.2.1.3. High Prevalence of Target Diseases 3.2.2. Market restraint analysis 3.2.2.1. Associated adverse effects of hyaluronic acid 3.2.2.2. High cost of products and related services 3.3. Hyaluronic Acid Market Analysis Tools 3.3.1. Industry Analysis - Porter’s 3.3.1.1. Supplier power 3.3.1.2. Buyer power 3.3.1.3. Substitution threat 3.3.1.4. Threat of new entrant 3.3.1.5. Competitive rivalry 3.3.2. PESTEL Analysis 3.3.2.1. Political landscape 3.3.2.2. Technological landscape 3.3.2.3. Economic landscape Chapter 4. Hyaluronic Acid Market: Application Estimates & Trend Analysis 4.1. Application Market Share, 2023 & 2030 4.2. Segment Dashboard 4.3. Global Hyaluronic Acid Market by Application Outlook 4.4. Market Size & Forecasts and Trend Analyses, 2018 - 2030 for the following 4.4.1. Dermal fillers 4.4.1.1. Market estimates and forecasts 2018 - 2030 (USD Million) 4.4.2. Osteoarthritis 4.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million) 4.4.2.2. Single-injection 4.4.2.2.1 Market estimates and forecasts 2018 - 2030 (USD Million) 4.4.2.3. Three-injection 4.4.2.3.1. Market estimates and forecasts 2018 - 2030 (USD Million) 4.4.2.3. Five-injection 4.4.2.3.1. Market estimates and forecasts 2018 - 2030 (USD Million) 4.4.3. Ophthalmic 4.4.3.3. Market estimates and forecasts 2018 - 2030 (USD Million) 4.4.4. Vesicoureteral reflux 4.4.2.3. Market estimates and forecasts 2018 - 2030 (USD Million) Chapter 5. Hyaluronic Acid Market: Regional Estimates & Trend Analysis 5.1. Regional Market Share Analysis, 2023 & 2030 5.2. Regional Market Dashboard 5.3. Global Regional Market Snapshot 5.4. Market Size, & Forecasts Trend Analysis, 2018 - 2030: 5.5. North America 5.5.1. U.S. 5.5.1.1. Key country dynamics 5.5.1.2. Regulatory framework/ reimbursement structure 5.5.1.3. Competitive scenario 5.5.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million) 5.5.2. Canada 5.5.2.1. Key country dynamics 5.5.2.2. Regulatory framework/ reimbursement structure 5.5.2.3. Competitive scenario 5.5.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million) 5.6. Europe 5.6.1. UK 5.6.1.1. Key country dynamics 5.6.1.2. Regulatory framework/ reimbursement structure 5.6.1.3. Competitive scenario 5.6.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million) 5.6.2. Germany 5.6.2.1. Key country dynamics 5.6.2.2. Regulatory framework/ reimbursement structure 5.6.2.3. Competitive scenario 5.6.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million) 5.6.3. France 5.6.3.1. Key country dynamics 5.6.3.2. Regulatory framework/ reimbursement structure 5.6.3.3. Competitive scenario 5.6.3.4. France market estimates and forecasts 2018 - 2030 (USD Million) 5.6.4. Italy 5.6.4.1. Key country dynamics 5.6.4.2. Regulatory framework/ reimbursement structure 5.6.4.3. Competitive scenario 5.6.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million) 5.6.5. Spain 5.6.5.1. Key country dynamics 5.6.5.2. Regulatory framework/ reimbursement structure 5.6.5.3. Competitive scenario 5.6.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million) 5.6.6. Norway 5.6.6.1. Key country dynamics 5.6.6.2. Regulatory framework/ reimbursement structure 5.6.6.3. Competitive scenario 5.6.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million) 5.6.7. Sweden 5.6.7.1. Key country dynamics 5.6.7.2. Regulatory framework/ reimbursement structure 5.6.7.3. Competitive scenario 5.6.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million) 5.6.8. Denmark 5.6.8.1. Key country dynamics 5.6.8.2. Regulatory framework/ reimbursement structure 5.6.8.3. Competitive scenario 5.6.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million) 5.7. Asia Pacific 5.7.1. Japan 5.7.1.1. Key country dynamics 5.7.1.2. Regulatory framework/ reimbursement structure 5.7.1.3. Competitive scenario 5.7.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million) 5.7.2. China 5.7.2.1. Key country dynamics 5.7.2.2. Regulatory framework/ reimbursement structure 5.7.2.3. Competitive scenario 5.7.2.4. China market estimates and forecasts 2018 - 2030 (USD Million) 5.7.3. India 5.7.3.1. Key country dynamics 5.7.3.2. Regulatory framework/ reimbursement structure 5.7.3.3. Competitive scenario 5.7.3.4. India market estimates and forecasts 2018 - 2030 (USD Million) 5.7.4. Australia 5.7.4.1. Key country dynamics 5.7.4.2. Regulatory framework/ reimbursement structure 5.7.4.3. Competitive scenario 5.7.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million) 5.7.5. South Korea 5.7.5.1. Key country dynamics 5.7.5.2. Regulatory framework/ reimbursement structure 5.7.5.3. Competitive scenario 5.7.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million) 5.7.6. Thailand 5.7.6.1. Key country dynamics 5.7.6.2. Regulatory framework/ reimbursement structure 5.7.6.3. Competitive scenario 5.7.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million) 5.8. Latin America 5.8.1. Brazil 5.8.1.1. Key country dynamics 5.8.1.2. Regulatory framework/ reimbursement structure 5.8.1.3. Competitive scenario 5.8.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million) 5.8.2. Mexico 5.8.2.1. Key country dynamics 5.8.2.2. Regulatory framework/ reimbursement structure 5.8.2.3. Competitive scenario 5.8.2.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million) 5.8.3. Argentina 5.8.3.1. Key country dynamics 5.8.3.2. Regulatory framework/ reimbursement structure 5.8.3.3. Competitive scenario 5.8.3.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million) 5.9. MEA 5.9.1. South Africa 5.9.1.1. Key country dynamics 5.9.1.2. Regulatory framework/ reimbursement structure 5.9.1.3. Competitive scenario 5.9.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million) 5.9.2. Saudi Arabia 5.9.2.1. Key country dynamics 5.9.2.2. Regulatory framework/ reimbursement structure 5.9.2.3. Competitive scenario 5.9.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million) 5.9.3. UAE 5.9.3.1. Key country dynamics 5.9.3.2. Regulatory framework/ reimbursement structure 5.9.3.3. Competitive scenario 5.9.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million) 5.9.4. Kuwait 5.9.4.1. Key country dynamics 5.9.4.2. Regulatory framework/ reimbursement structure 5.9.4.3. Competitive scenario 5.9.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million) Chapter 6. Competitive Landscape 6.1. Recent Developments & Impact Analysis, By Key Market Participants 6.2. Company/Competition Categorization 6.3. Vendor Landscape 6.3.1. List of key distributors and channel partners 6.3.2. Key customers 6.3.3. Key company market share analysis, 2023 6.3.4. Allergan 6.3.4.1. Company overview 6.3.4.2. Financial performance 6.3.4.3. Product benchmarking 6.3.4.4. Strategic initiatives 6.3.5. Sanofi 6.3.5.1. Company overview 6.3.5.2. Financial performance 6.3.5.3. Product benchmarking 6.3.5.4. Strategic initiatives 6.3.6. Genzyme Corporation 6.3.6.1. Company overview 6.3.6.2. Financial performance 6.3.6.3. Product benchmarking 6.3.6.4. Strategic initiatives 6.3.7. Anika Therapeutics, Inc. 6.3.7.1. Company overview 6.3.7.2. Financial performance 6.3.7.3. Product benchmarking 6.3.7.4. Strategic initiatives 6.3.8. Salix Pharmaceuticals 6.3.8.1. Company overview 6.3.8.2. Financial performance 6.3.8.3. Product benchmarking 6.3.8.4. Strategic initiatives 6.3.9. Seikagaku Corporation 6.3.9.1. Company overview 6.3.9.2. Financial performance 6.3.9.3. Product benchmarking 6.3.9.4. Strategic initiatives 6.3.10. F. Hoffmann-La Roche Ag 6.3.10.1. Company overview 6.3.10.2. Financial performance 6.3.10.3. Product benchmarking 6.3.10.4. Strategic initiatives 6.3.11. Galderma Laboratories L.P. 6.3.11.1. Company overview 6.3.11.2. Financial performance 6.3.11.3. Product benchmarking 6.3.11.4. Strategic initiatives 6.3.12. Zimmer Biomet 6.3.12.1. Company overview 6.3.12.2. Financial performance 6.3.12.3. Product benchmarking 6.3.12.4. Strategic initiatives 6.3.13. Smith & Nephew Plc 6.3.13.1. Company overview 6.3.13.2. Financial performance 6.3.13.3. Product benchmarking 6.3.13.4. Strategic initiatives 6.3.14. Ferring B.V. 6.3.14.1. Company overview 6.3.14.2. Financial performance 6.3.14.3. Product benchmarking 6.3.14.4. Strategic initiatives 6.3.15. Lifecore Biomedical, LLC 6.3.15.1. Company overview 6.3.15.2. Financial performance 6.3.15.3. Product benchmarking 6.3.15.4. Strategic initiatives 6.3.16. HTL Biotechnology 6.3.16.1. Company overview 6.3.16.2. Financial performance 6.3.16.3. Product benchmarking 6.3.16.4. Strategic initiatives 6.3.17. Shiseido Company, Limited 6.3.17.1. Company overview 6.3.17.2. Financial performance 6.3.17.3. Product benchmarking 6.3.17.4. Strategic initiatives 6.3.18. Bloomage Biotechnology Corporation Limited 6.3.18.1. Company overview 6.3.18.2. Financial performance 6.3.18.3. Product benchmarking 6.3.18.4. Strategic initiatives 6.3.19. LG Life Sciences Ltd (LG Chem.) 6.3.19.1. Company overview 6.3.19.2. Financial performance 6.3.19.3. Product benchmarking 6.3.19.4. Strategic initiatives 6.3.20. Maruha Nichiro, Inc. 6.3.20.1. Company overview 6.3.20.2. Financial performance 6.3.20.3. Product benchmarking 6.3.20.4. Strategic initiatives
SummaryHyaluronic Acid Market Growth & Trends Table of ContentsTable of ContentsChapter 1. Methodology and Scope 1.1. Market Segmentation & Scope 1.2. Segment Definitions 1.2.1. Application 1.2.2. Regional scope 1.2.3. Estimates and forecasts timeline 1.3. Research Methodology 1.4. Information Procurement 1.4.1. Purchased database 1.4.2. GVR’s internal database 1.4.3. Secondary sources 1.4.4. Primary research 1.4.5. Details of primary research 1.4.5.1. Data for primary interviews in North America 1.4.5.2. Data for primary interviews in Europe 1.4.5.3. Data for primary interviews in Asia Pacific 1.4.5.4. Data for primary interviews in Latin America 1.4.5.5. Data for Primary interviews in MEA 1.5. Information or Data Analysis 1.5.1. Data analysis models 1.6. Market Formulation & Validation 1.7. Model Details 1.7.1. Commodity flow analysis (Model 1) 1.7.2. Approach 1: Commodity flow approach 1.7.3. Volume price analysis (Model 2) 1.7.4. Approach 2: Volume price analysis 1.8. List of Secondary Sources 1.9. List of Primary Sources 1.10. Objectives Chapter 2. Executive Summary 2.1. Market Outlook 2.2. Segment Outlook 2.2.1. Application 2.2.2. Regional outlook 2.3. Competitive Insights Chapter 3. Hyaluronic Acid Market Variables, Trends & Scope 3.1. Market Lineage Outlook 3.1.1. Parent market outlook 3.1.2. Related/ancillary market outlook 3.2. Market Dynamics 3.2.1. Market driver analysis 3.2.1.1. Increasing Geriatric Population 3.2.1.2. Growing Awareness for Antiaging Products 3.2.1.3. High Prevalence of Target Diseases 3.2.2. Market restraint analysis 3.2.2.1. Associated adverse effects of hyaluronic acid 3.2.2.2. High cost of products and related services 3.3. Hyaluronic Acid Market Analysis Tools 3.3.1. Industry Analysis - Porter’s 3.3.1.1. Supplier power 3.3.1.2. Buyer power 3.3.1.3. Substitution threat 3.3.1.4. Threat of new entrant 3.3.1.5. Competitive rivalry 3.3.2. PESTEL Analysis 3.3.2.1. Political landscape 3.3.2.2. Technological landscape 3.3.2.3. Economic landscape Chapter 4. Hyaluronic Acid Market: Application Estimates & Trend Analysis 4.1. Application Market Share, 2023 & 2030 4.2. Segment Dashboard 4.3. Global Hyaluronic Acid Market by Application Outlook 4.4. Market Size & Forecasts and Trend Analyses, 2018 - 2030 for the following 4.4.1. Dermal fillers 4.4.1.1. Market estimates and forecasts 2018 - 2030 (USD Million) 4.4.2. Osteoarthritis 4.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million) 4.4.2.2. Single-injection 4.4.2.2.1 Market estimates and forecasts 2018 - 2030 (USD Million) 4.4.2.3. Three-injection 4.4.2.3.1. Market estimates and forecasts 2018 - 2030 (USD Million) 4.4.2.3. Five-injection 4.4.2.3.1. Market estimates and forecasts 2018 - 2030 (USD Million) 4.4.3. Ophthalmic 4.4.3.3. Market estimates and forecasts 2018 - 2030 (USD Million) 4.4.4. Vesicoureteral reflux 4.4.2.3. Market estimates and forecasts 2018 - 2030 (USD Million) Chapter 5. Hyaluronic Acid Market: Regional Estimates & Trend Analysis 5.1. Regional Market Share Analysis, 2023 & 2030 5.2. Regional Market Dashboard 5.3. Global Regional Market Snapshot 5.4. Market Size, & Forecasts Trend Analysis, 2018 - 2030: 5.5. North America 5.5.1. U.S. 5.5.1.1. Key country dynamics 5.5.1.2. Regulatory framework/ reimbursement structure 5.5.1.3. Competitive scenario 5.5.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million) 5.5.2. Canada 5.5.2.1. Key country dynamics 5.5.2.2. Regulatory framework/ reimbursement structure 5.5.2.3. Competitive scenario 5.5.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million) 5.6. Europe 5.6.1. UK 5.6.1.1. Key country dynamics 5.6.1.2. Regulatory framework/ reimbursement structure 5.6.1.3. Competitive scenario 5.6.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million) 5.6.2. Germany 5.6.2.1. Key country dynamics 5.6.2.2. Regulatory framework/ reimbursement structure 5.6.2.3. Competitive scenario 5.6.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million) 5.6.3. France 5.6.3.1. Key country dynamics 5.6.3.2. Regulatory framework/ reimbursement structure 5.6.3.3. Competitive scenario 5.6.3.4. France market estimates and forecasts 2018 - 2030 (USD Million) 5.6.4. Italy 5.6.4.1. Key country dynamics 5.6.4.2. Regulatory framework/ reimbursement structure 5.6.4.3. Competitive scenario 5.6.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million) 5.6.5. Spain 5.6.5.1. Key country dynamics 5.6.5.2. Regulatory framework/ reimbursement structure 5.6.5.3. Competitive scenario 5.6.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million) 5.6.6. Norway 5.6.6.1. Key country dynamics 5.6.6.2. Regulatory framework/ reimbursement structure 5.6.6.3. Competitive scenario 5.6.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million) 5.6.7. Sweden 5.6.7.1. Key country dynamics 5.6.7.2. Regulatory framework/ reimbursement structure 5.6.7.3. Competitive scenario 5.6.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million) 5.6.8. Denmark 5.6.8.1. Key country dynamics 5.6.8.2. Regulatory framework/ reimbursement structure 5.6.8.3. Competitive scenario 5.6.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million) 5.7. Asia Pacific 5.7.1. Japan 5.7.1.1. Key country dynamics 5.7.1.2. Regulatory framework/ reimbursement structure 5.7.1.3. Competitive scenario 5.7.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million) 5.7.2. China 5.7.2.1. Key country dynamics 5.7.2.2. Regulatory framework/ reimbursement structure 5.7.2.3. Competitive scenario 5.7.2.4. China market estimates and forecasts 2018 - 2030 (USD Million) 5.7.3. India 5.7.3.1. Key country dynamics 5.7.3.2. Regulatory framework/ reimbursement structure 5.7.3.3. Competitive scenario 5.7.3.4. India market estimates and forecasts 2018 - 2030 (USD Million) 5.7.4. Australia 5.7.4.1. Key country dynamics 5.7.4.2. Regulatory framework/ reimbursement structure 5.7.4.3. Competitive scenario 5.7.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million) 5.7.5. South Korea 5.7.5.1. Key country dynamics 5.7.5.2. Regulatory framework/ reimbursement structure 5.7.5.3. Competitive scenario 5.7.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million) 5.7.6. Thailand 5.7.6.1. Key country dynamics 5.7.6.2. Regulatory framework/ reimbursement structure 5.7.6.3. Competitive scenario 5.7.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million) 5.8. Latin America 5.8.1. Brazil 5.8.1.1. Key country dynamics 5.8.1.2. Regulatory framework/ reimbursement structure 5.8.1.3. Competitive scenario 5.8.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million) 5.8.2. Mexico 5.8.2.1. Key country dynamics 5.8.2.2. Regulatory framework/ reimbursement structure 5.8.2.3. Competitive scenario 5.8.2.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million) 5.8.3. Argentina 5.8.3.1. Key country dynamics 5.8.3.2. Regulatory framework/ reimbursement structure 5.8.3.3. Competitive scenario 5.8.3.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million) 5.9. MEA 5.9.1. South Africa 5.9.1.1. Key country dynamics 5.9.1.2. Regulatory framework/ reimbursement structure 5.9.1.3. Competitive scenario 5.9.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million) 5.9.2. Saudi Arabia 5.9.2.1. Key country dynamics 5.9.2.2. Regulatory framework/ reimbursement structure 5.9.2.3. Competitive scenario 5.9.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million) 5.9.3. UAE 5.9.3.1. Key country dynamics 5.9.3.2. Regulatory framework/ reimbursement structure 5.9.3.3. Competitive scenario 5.9.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million) 5.9.4. Kuwait 5.9.4.1. Key country dynamics 5.9.4.2. Regulatory framework/ reimbursement structure 5.9.4.3. Competitive scenario 5.9.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million) Chapter 6. Competitive Landscape 6.1. Recent Developments & Impact Analysis, By Key Market Participants 6.2. Company/Competition Categorization 6.3. Vendor Landscape 6.3.1. List of key distributors and channel partners 6.3.2. Key customers 6.3.3. Key company market share analysis, 2023 6.3.4. Allergan 6.3.4.1. Company overview 6.3.4.2. Financial performance 6.3.4.3. Product benchmarking 6.3.4.4. Strategic initiatives 6.3.5. Sanofi 6.3.5.1. Company overview 6.3.5.2. Financial performance 6.3.5.3. Product benchmarking 6.3.5.4. Strategic initiatives 6.3.6. Genzyme Corporation 6.3.6.1. Company overview 6.3.6.2. Financial performance 6.3.6.3. Product benchmarking 6.3.6.4. Strategic initiatives 6.3.7. Anika Therapeutics, Inc. 6.3.7.1. Company overview 6.3.7.2. Financial performance 6.3.7.3. Product benchmarking 6.3.7.4. Strategic initiatives 6.3.8. Salix Pharmaceuticals 6.3.8.1. Company overview 6.3.8.2. Financial performance 6.3.8.3. Product benchmarking 6.3.8.4. Strategic initiatives 6.3.9. Seikagaku Corporation 6.3.9.1. Company overview 6.3.9.2. Financial performance 6.3.9.3. Product benchmarking 6.3.9.4. Strategic initiatives 6.3.10. F. Hoffmann-La Roche Ag 6.3.10.1. Company overview 6.3.10.2. Financial performance 6.3.10.3. Product benchmarking 6.3.10.4. Strategic initiatives 6.3.11. Galderma Laboratories L.P. 6.3.11.1. Company overview 6.3.11.2. Financial performance 6.3.11.3. Product benchmarking 6.3.11.4. Strategic initiatives 6.3.12. Zimmer Biomet 6.3.12.1. Company overview 6.3.12.2. Financial performance 6.3.12.3. Product benchmarking 6.3.12.4. Strategic initiatives 6.3.13. Smith & Nephew Plc 6.3.13.1. Company overview 6.3.13.2. Financial performance 6.3.13.3. Product benchmarking 6.3.13.4. Strategic initiatives 6.3.14. Ferring B.V. 6.3.14.1. Company overview 6.3.14.2. Financial performance 6.3.14.3. Product benchmarking 6.3.14.4. Strategic initiatives 6.3.15. Lifecore Biomedical, LLC 6.3.15.1. Company overview 6.3.15.2. Financial performance 6.3.15.3. Product benchmarking 6.3.15.4. Strategic initiatives 6.3.16. HTL Biotechnology 6.3.16.1. Company overview 6.3.16.2. Financial performance 6.3.16.3. Product benchmarking 6.3.16.4. Strategic initiatives 6.3.17. Shiseido Company, Limited 6.3.17.1. Company overview 6.3.17.2. Financial performance 6.3.17.3. Product benchmarking 6.3.17.4. Strategic initiatives 6.3.18. Bloomage Biotechnology Corporation Limited 6.3.18.1. Company overview 6.3.18.2. Financial performance 6.3.18.3. Product benchmarking 6.3.18.4. Strategic initiatives 6.3.19. LG Life Sciences Ltd (LG Chem.) 6.3.19.1. Company overview 6.3.19.2. Financial performance 6.3.19.3. Product benchmarking 6.3.19.4. Strategic initiatives 6.3.20. Maruha Nichiro, Inc. 6.3.20.1. Company overview 6.3.20.2. Financial performance 6.3.20.3. Product benchmarking 6.3.20.4. Strategic initiatives
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療機器)の最新刊レポート
Grand View Research社の医療機器分野での最新刊レポート
本レポートと同じKEY WORD(hyaluronic acid)の最新刊レポートよくあるご質問Grand View Research社はどのような調査会社ですか?グランドビューリサーチ(Grand View Research)は通信技術、化学品、材料、ヘルスケア、エネルギーなど広範な市場を対象にした調査報告書を出版しています。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|